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Abstract
Background: Only few countries have cohorts enabling specific and up-to-date cardiovascular disease (CVD) risk estimation.
Individual risk assessment based on study samples that differ too much from the target population could jeopardize the
benefit of risk charts in general practice. Our aim was to provide up-to-date and valid CVD risk estimation for a Swiss
population using a novel record linkage approach.
Methods: Anonymous record linkage was used to follow-up (for mortality, until 2008) 9,853 men and women aged 25–74
years who participated in the Swiss MONICA (MONItoring of trends and determinants in CVD) study of 1983–92. The linkage
success was 97.8%, loss to follow-up 1990–2000 was 4.7%. Based on the ESC SCORE methodology (Weibull regression), we
used age, sex, blood pressure, smoking, and cholesterol to generate three models. We compared the 1) original SCORE
model with a 2) recalibrated and a 3) new model using the Brier score (BS) and cross-validation.
Results: Based on the cross-validated BS, the new model (BS = 1410761026) was somewhat more appropriate for risk
estimation than the original (BS = 1419061026) and the recalibrated (BS = 1417261026) model. Particularly at younger age,
derived absolute risks were consistently lower than those from the original and the recalibrated model which was mainly
due to a smaller impact of total cholesterol.
Conclusion: Using record linkage of observational and routine data is an efficient procedure to obtain valid and up-to-date
CVD risk estimates for a specific population.
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Introduction
The SCORE (Systematic COronary Risk Evaluation) project
from the European Society of Cardiology (ESC) pooled a dozen of
prospective cohorts from European countries. [1] The aim was to
provide a method to estimate absolute risk for fatal cardiovascular
disease (CVD) based on major CVD risk factors. [1] The result is a
clinically useful and evidence-based tool for risk prediction widely
used in clinical practice. [2] However, for several reasons, CVD
risk estimation may be misleading. First, there is substantial
variation in the prevalence of CVD risk factors, mortality and
trends of CVD across populations and with respect to the
relationship between CVD risk factors and risk of death.[1,3–5]
Such differences are not fully taken into account by pooled data
originating from different countries, even if separate models for
high and low risk countries are provided for SCORE. [1,6]
Second, there is long latency between data collection and the
generation of risk scores and their use by physicians. As a
consequence, risk formulas derived from persons having died, for
example, 40 years ago, are used in today’s context and changes in
risk factors in the population and medical progress are not taken
into account. Third, there has been a dramatic decrease in CVD
mortality in most countries with a concomitant increase in life
expectancy. [3,7] These demographic changes should be reflected
in the risk scores, e.g. by shifting the prediction age classes towards
older ages. Currently, the SCORE risk function is restricted to a
maximum age of 65 years. [1].
Unfortunately, most European countries - particularly those at
low risk - do not have cohort studies necessary to provide country
specific and up-to-date risk functions. Therefore, these countries
use risk factor coefficients defining the ‘‘individual hazardousness’’
from ‘‘foreign’’ populations. Previous attempts to adapt the
SCORE were limited by the fact that mortality did not stem
from the population that provided CVD risk factors (health survey)
PLOS ONE | www.plosone.org 1 February 2013 | Volume 8 | Issue 2 | e56149
but from the general population (death registry).[8–10] This
precludes considering changes in the association between risk
factors and their combination and the risk of death.
In this study we aimed at adapting the SCORE method in a
way that it provides up-to-date and population specific valid
estimates by using available routine and observational data. For
this purpose, we combined data from the Swiss National Cohort
(SNC, a record linkage of data from the census, death and
migration registries) with data from a CVD health survey. We
aimed at comparing the original SCORE model (low-risk
countries) with a recalibrated version of the original SCORE
model and with a new model including coefficients for risk factors
derived from our linked database. In Switzerland, CVD mortality
has substantially decreased over the past three decades, resulting in
very low rates compared to other countries. [3,7] In contrast, the
prevalence of major CVD risk factors remained relatively stable or
only slightly declined, but is still lower than in most other
countries. [3,4].
Methods
Population
We used data from the Swiss MONICA population survey.
MONICA is an international project of the World Health
Organization (WHO) aimed at monitoring trends and determi-
nants in CVD. [11] In Switzerland, the study has been conducted
in the cantons Vaud/Fribourg and Ticino and in three waves
during period 1983–92 in men and women aged 25–74. Of the
initially sampled persons, between 54% and 78% participated in
the study.[12–14] Lack of mortality follow-up was overcome by an
anonymous record linkage with the SNC. [14,15] Approval (Nr.
13/06) was obtained from the Ethics Committee of the Canton of
Zurich. Details of the study sample are given in Table 1.
Record Linkage Procedure
In order to determine vital status of MONICA participants, we
used an anonymous record linkage with the SNC. The SNC
encompasses all residents of Switzerland included in the national
censuses of 1990 and 2000 (6.8 and 7.3 million, respectively). As
described elsewhere, deterministic and probabilistic methods were
used to link anonymised census, death and emigration records.
[15] In a second phase, SNC information was linked to MONICA
data. This additional record linkage was also entirely anonymous.
The linkage was based on procedures including all potential
identification variables, i.e. variables available in MONICA and in
the SNC. The minimal required information for a promising
record linkage was sex, exact date of birth and place of residence
(community). Additional identification variables were nationality,
marital status, educational category and profession. [14].
As the same individual could be sampled in more than one
MONICA wave, all participants with identical sex/date of birth/
place of residence were checked for repeated sampling, with a
plausibility test based on profession, body height, body weight and
blood pressure.
Record linkage between MONICA and SNC was performed
stepwise, with satisfactorily linked individuals excluded from
succeeding steps (MONICA III, which was conducted in 1992/
3, is not involved in the steps 2 and 5, because no deaths occurred
before 1990 among participants):
1) MONICA community = 1990 census community of
residence
Table 1. Characteristics (counts, means and proportions) of the Swiss MONICA study sample and the ESC SCORE sample.
MONICA ESC SCORE*
Men Women Men Women
Countries Switzerland 3 European*
Recruitment years 1983–1992 1974–1988
Participation rate (%) 54–78 36–75
95th centile of follow-up (years) 23.9 10.1–13.7
Participants with mortality follow-up (n) 4784 4662 37183 31598
Mean age at baseline; standard deviation (years) 47.0; 11.3 47.2; 11.5 NR
Age range at baseline (years) 25–74 19–80
Deaths
Cardiovascular disease (% of all deaths) 29.9 28.0 NR
Coronary heart disease (n) 143 53 NR
Coronary heart disease (% of all CVD) 52.8 35.1 47–77 38–70
Non-coronary CVD (n) 128 98 NR
All causes 906 539 NR
Deaths in persons aged $65 years (% of all deaths) 67.0 74.0 NR
Current smoker (%) 32.2 24.8 46–54 12–22
Systolic blood pressure (mmHg) 132.0 126.0 132–136 120–133
Mean total Cholesterol (mmol/l) 6.2 6.0 5.6–6.0 5.5–6.1
Mean total-to-HDL-cholesterol ratio 5.7 4.4 4.4–4.8 3.8–4.0
*‘‘Low-risk’’ countries: Belgium (n = 10,641), Italy (n = 53,439), Spain (n = 4,701).
HDL: High-density lipoprotein.
NR: not reported.
MONICA: MONItoring of trends and determinants in CArdiovascular disease.
doi:10.1371/journal.pone.0056149.t001
Population-Specific Cardiovascular Risk Charts
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2) Participants of MONICA I, II: MONICA community = -
community in mortality records (only deaths occurred
before 1990 census)
3) MONICA community = 1985 community of residence
(based on 1990 census)
4) MONICA community = 2000 or 1995 community of
residence (based on 2000 census)
5) Participants of MONICA I, II: linkage with other
community based on mortality statistics (only deaths
occurred before the 1990 census)
6) linkage with other community of 1990 census in the same
canton
7) linkage with community of 1990 census in another canton
8) manual control and optimization (check of remaining
unlinked MONICA participants for potential partner
records in the 1990 census and the 1984–90 mortality
records. Typically these records showed discordances
regarding date of birth, place of residence and occupation,
which prevented automated record linkage. Still, consider-
ing all available information and potential alternative links,
it was inferred that the records referred to the same
individual)
MONICA wave, region of residence (Vaud/Fribourg, Ticino),
age, sex, nationality (Swiss or foreign), marital status and
educational level (mandatory, upper secondary, tertiary, university
education) were included as independent variables in a logistic
regression model to analyse the odds for linkage failures or loss to
follow-up between the censuses of 1990 and 2000.
Of the eligible 10,160 MONICA participants, 97.8% could be
linked to a census (9,737 in 1990 and 8,749 in 2000), mortality
(1,526 for period 1984–2008) and/or emigration record (320 for
period 1990–2008). Eighty-three participants of the 1992 wave of
MONICA could only be linked to the preceding 1990 census but
not to a subsequent census, mortality or emigration record, thus
leaving 9,853 individuals for survival analysis. Loss to follow-up
between 1990 and 2000 amounted to 4.7%. Since there was no
census at the end of the study, loss to follow-up after the 2000
census could not be determined. Hence, all 7,854 individuals
linked to the 2000 census but not to a succeeding death or
emigration record were considered as being alive. [14].
Exposure and Outcome
Measurements and blood sampling procedures were described
earlier. [12,13] We defined smoking as current smoking
irrespective of the number of cigarettes. Non-smokers included
former and never smokers. Systolic blood pressure was computed
as the mean of two or three successive measurements. Outcome
data (death with underlying cause) was derived from the Swiss
national death registry; this information is included in the SNC.
[15] Fatal CVD events were defined according to the International
Classification of Diseases (ICD) revisions 8 (ICD-8:390–458, until
1994) and 10 (ICD-10: I00-I99, since 1995). For recalibration, we
divided CVD into coronary heart disease (CHD; ICD-8:410–414,
ICD-10: I20–I25) and non-coronary CVD, according to the
literature. [1].
Survival Analysis
Risk score calculation based on Weibull proportional hazards
regression models. The corresponding hazard function is:
h(t)~exp(b0Z)exp(a)p(t-20)p{1
where Z contains the values of the covariates and b is the vector of
the corresponding coefficients. The other parameters, a and p, are
the logarithm of the intercept and the scale parameter, respec-
tively. As in, [1] the time variable t in the hazard function is the
person’s age at either 1) date of death (from mortality records) or 2)
the censoring time point, i.e., 12/31/2008.
Individual 10 year risk scores were obtained using three
approaches: 1) based on the original SCORE coefficients as
described in [1]; 2) based on a recalibration of the original
SCORE model with the methodology described in [16]; 3) based
on new coefficients derived from Weibull regression models
applied to our data.
Models
We used the original SCORE with its coefficients for low-risk
countries (Belgium n= 10,641; Italy, n = 53,439; Spain, n= 4,701)
as reference. [1] We recalibrated the original model [1] by fitting
two new Weibull regression models (one for CHD and one for
non-coronary CVD) to our data. In these models, only the
parameters a and p were estimated, the remaining coefficients
Table 2. Parameters and coefficients of the three models.
Original SCORE Recalibrated New
CHD non-CHD CHD non-CHD
CVD, Total
cholesterol CVD, Cholesterol ratio
a men 222.1 226.7 229.5 (232.5; 226.4) 233.5 (237.2; 229.9) 230.7 (233.1; 228.4) 231.5 (233.9; 229.1)
p men 4.71 5.64 6.43 (5.68; 7.18) 7.41 (6.52; 8.30) 6.99 (6.41; 7.57) 7.05 (6.46; 7.63)
a women 229.8 231.0 246.9 (254.6; 239.3) 244.3 (249.7; 238.9) 245.9 (250.3; 241.4) 246.0 (250.4; 241.5)
p women 6.36 6.62 10.38 (8.55; 12.22) 9.92 (8.62; 11.22) 10.49 (9.41; 11.57) 10.40 (9.32; 11.48)
Current smoking 0.71 0.63 0.56 (0.35; 0.78) 0.53 (0.32; 0.75)
Cholesterol (mmol/l or ratio) 0.24 0.02 0.02 (20.06; 0.10) 0.09 (0.06; 0.12)
Systolic blood pressure (mmHg) 0.018 0.022 0.01 (0.00; 0.01) 0.01 (0.00; 0.01)
Brier score (mean) 1419061026 1417261026 1410761026 1418461026
*‘‘Low-risk’’ countries: Belgium (n = 10,641), Italy (n = 53,439), Spain (n = 4,701).
Figures in brackets are 95% confidence intervals, not given for the original SCORE model.
CVD: cardiovascular disease; CHD: coronary heart disease; non-CHD: non-coronary CVD.
Cholesterol ratio: Total-to-HDL(high-density lipoprotein)-cholesterol.
doi:10.1371/journal.pone.0056149.t002
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from the two original models being fixed and included as an offset.
This corresponds to recalibration as described in, [16] where the
values of the covariates and their coefficients serve as offset and the
intercept and remaining parameters are shifted to better represent
the characteristics of the actual population. Additionally, two
completely new models were calculated with current smoking,
systolic BP (mmHg) and total cholesterol or, alternatively,
cholesterol ratio (total-to-HDL-cholesterol) as covariates. To keep
these two models as simple as possible, we calculated only one joint
model for CVD deaths and omitted the partition into CHD and
non-coronary CVD deaths. We took this somewhat arbitrary
decision to circumvent misclassification of deaths, which could
potentially result in information bias. As shown in the original
SCORE sample, there were large variations in the proportion of
non-coronary CVD cases, possibly due to cultural differences in
assignment of causes of death. [1] In Switzerland, the extent to
which CHD and non-coronary CVD deaths decreased over the
past decades was similar, suggesting similar pathophysiological
mechanisms and comparable progress in medical treatment. [7].
Model Comparison
In order to compare the predictive abilities of the different risk
scores (original, recalibrated, new), we calculated the Brier score.
[17] The Brier score measures the mean squared difference
between the risk score and the actual outcome. The lower this
deviation, the better the respective risk prediction model. The
Figure 1. Chart for absolute 10-year risk of fatal cardiovascular disease based on the new model using total cholesterol. 9,446
participants of the Swiss MONICA study conducted 1983–92, ages 25–74 years at baseline. MONICA: MONItoring of trends and determinants in
CArdiovascular disease, entire population with full follow-up Each risk percentage is calculated using a combination of given risk factor values. E.g., a
man aged 65, smoker, with a systolic blood pressure of 180 and a total cholesterol of 6 mmol/L has an absolute risk (within the next 10 years) of fatal
CVD of 14%.
doi:10.1371/journal.pone.0056149.g001
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Brier score accounts for both discrimination (i.e. correct classifi-
cation in different outcome groups) and calibration (agreement of
the predictions with the true risk). [16] This is a clear advantage
over other common methods for prediction assessment, especially
the receiver operating characteristic (ROC) curve and the net
reclassification improvement (NRI) which both focus on discrim-
ination. Discrimination is important in a diagnostic setting where
the classification of individuals into different groups is the main
interest. However, in a prognostic setting, where individuals
probabilities of future events are the main goal, calibration is of
paramount importance and should not be ignored. [18] Moreover,
the Brier score is easy to interpret and is not dependent on an
arbitrary definition of thresholds for the classification of individual
risk scores to different risk groups.
As the Brier score would be too optimistic in the case where
model fitting and assessment are performed using the same data
(i.e. for the recalibrated and the new model), we used leave-one-
out cross-validation: after one person is excluded from the data set,
the Weibull regression model is re-fitted to the remaining data,
and the risk score is then estimated for the person left out. This was
repeated 9,853 times, i.e. once for each individual in the data set,
and used to obtain the mean Brier score. After the models could be
prioritized with the Brier score, we performed a Bland-Altman
analysis in order to assess the agreement and clinical relevance of
the differences in risk score between the selected model and the
Figure 2. Chart for absolute 10-year risk of fatal cardiovascular disease based on the new model using cholesterol ratio. 9,446
participants of the Swiss MONICA study conducted 1983–92, ages 25–74 years at baseline MONICA: MONItoring of trends and determinants in
CArdiovascular disease, entire population with full follow-up HDL: High-density lipoprotein Each risk percentage is calculated using a combination of
given risk factor values. E.g., a man aged 65, smoker, with a systolic blood pressure of 180 and a total cholesterol of 6 mmol/L has an absolute risk
(within the next 10 years) of fatal CVD of 14%.
doi:10.1371/journal.pone.0056149.g002
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original SCORE model, (see Supporting Information, Figures S3–
S4).
General descriptive analyses and the fitting of survival models
were performed with Stata 11 (Stata Corp, College Station, TX,
USA). The actual risk calculations based on these results were
obtained with R 2.14.1 (The R Foundation for Statistical
Computing).
Results
Table 1 compares the characteristics of the Swiss MONICA
study population and the low-risk cohorts used to compute the
ESC SCORE. The low-risk cohorts from the SCORE were
recruited earlier and were followed over a shorter period of time
than the MONICA sample. The age range was a bit wider in the
SCORE sample. The proportion of CHD based on all CVD was
lower in the MONICA sample, particularly in women. Amongst
MONICA participants, the proportion of smokers was lower in
men but higher in women. In MONICA men and women, mean
blood pressure was in the range of the SCORE countries, while
total cholesterol was above the range (6.2 vs. 6.0 mmol/l). In both
sexes, cholesterol ratio was higher in the MONICA than in the
SCORE sample.
Table 2 shows the estimated model parameters and coefficients
from the original SCORE, the recalibrated and the new model.
The small values suggest that all models are able to predict
mortality quite accurately. Nevertheless there are distinct relative
differences. With 1410761026, the new model with total
cholesterol had the lowest mean Brier score, which means that it
is the most accurate model for predicting CVD risk in our sample.
In order to substantiate the results provided by the Brier score, we
plotted and interpreted Bland-Altman plots. They show that the
variation in risk predictions between the original and the new
model not only leads to different mean Brier scores. As shown in
Figures S3–S4 (Supporting Information), the variation itself is also
substantial and of clinically relevant.
Figure 1 shows the risk chart based on the new model with total
cholesterol, extended to higher age categories compared to the
original SCORE. In men younger than 50 years and women
younger than 55 years, risks remained approximately constant.
This was also the case in the recalibrated model (Supporting
Information, Figure S1). Particularly in younger age classes (50–60
years), absolute risks were substantially smaller in the new model
than in the recalibrated and original SCORE model (Supporting
Information, Figure S2). The difference attenuated with increasing
age. In contrast, the impact of total cholesterol remained
consistent over all ages: there was only a minimal risk gradient
over the cholesterol range (4–8 mmol/L) in the new model, while
in the original and the recalibrated model the relative risk of the
highest vs. the lowest cholesterol concentration ranged between
1.5 and 2.0. Still, the impact of total cholesterol was lower than
that of systolic blood pressure (relative risk of 3.0 to 5.0 from 120–
180 mmHg). As shown in Figure 2, the new model based on total-
to-HDL cholesterol ratio (instead of total cholesterol) discriminat-
ed more strongly older persons (70+ years) at high and low risk.
Discussion
Main Results
Using linked data and relying on the methodology of the ESC
SCORE, we evaluated how well three different models were able
to predict fatal CVD events in the population of Switzerland. The
new model was more appropriate than the original and the
recalibrated SCORE, the latter showing however some improve-
ment. Compared to the new model, both the original and the
recalibrated models overestimated CVD risk in Switzerland. The
largest variation was found in younger persons and for the impact
of cholesterol, which was smaller in the new model.
Comparison with Other Studies
To the best of our knowledge, there have been no previous
attempts similar to ours. There were various efforts to adapt
SCORE in order to obtain more valid estimations of CVD risk in
a specific population. However, such recalibrations are limited by
the fact that they rely on risk factors from persons participating in
a health survey and on mortality data from the general
population.[8–10] Information about hazard ratios (HR), i.e. the
specific effect of each CVD risk factor on mortality is crucial for
determination of absolute CVD risks in a given population. With
recalibration, this information does not arise from the target
population but still stems from a ‘‘foreign’’ population. When
SCORE (low-risk populations) is used, recalibration studies
showed slight risk underestimation for an urban population from
Greece [9] and the Spanish MONICA population [8] and a small
overestimation for an urban population from Switzerland. [10]
Overestimation also occurred in Norway, where the implementa-
tion of guidelines based on SCORE would have doubled the
number of persons in need of CVD medication for primary
prevention. [6] Conversely, relatively small variations (small
overestimation) were found comparing the original SCORE with
our recalibrated model (Supporting Information, Figure S1).
Possible Explanations for Overestimation
In the past four decades, death from CVD has markedly
decreased in Switzerland. [7] To date, Switzerland is amongst the
European countries with the lowest CHD and stroke mortality
rates. [3] This trend may rather be due to improvements in
screening and treatment of CVD and its risk factors, while the
prevalence of CVD risk factors has remained stable or even
slightly increased over time. [4,19] Blood pressure and cholesterol
lowering medication have increased and in-hospital mortality of
acute myocardial infarction has decreased. [19,20] The data used
for risk estimation of SCORE was gathered between 1974 and
1992. Applying this ‘‘historical’’ data to a much more recent
population is implicitly prone to overestimation, particularly in
younger individuals.
Another reason for the difference between our new model and
the original SCORE model could be the different follow-up time
which was about twice as long in our sample. A long follow-up
time could ‘‘wash out’’ the relationship between a risk factor and
mortality: the likelihood that the individual’s risk factors change
increases with increasing follow-up time.
The variation between the new and the original/recalibrated
model was mainly due to cholesterol which had a much smaller
impact in our sample. Using total-to-HDL-cholesterol ratio
provided only a small improvement (Figure 2). As shown
previously, the association of CVD death with cholesterol
parameters was definitely weaker than with blood pressure. [21]
We found a similar pattern (weak impact of cholesterol and
consistent/strong impact of blood pressure) when using data from
an older study conducted in Switzerland in 1977 (results not
published). [22].
Strengths of Our Approach
Our approach has the advantage that it not only considers
prevalence of CVD risk factors and CVD mortality but also
includes relative CVD risks (i.e. HR). The latter may strongly vary
between European countries. [5] Relative risks allow for a more
Population-Specific Cardiovascular Risk Charts
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appropriate estimation of CVD mortality in a specific sample
because they take into account population specific variations
associated with risk factors and variations over age and between
sexes. Moreover, up-to-date data can be obtained with compara-
bly little effort. A CVD cohort would be much more costly and
would require 20 years or so to provide enough deaths for robust
analyses. Our approach also allows continuous mortality follow-
up, thus taking into account changing circumstances such as
improvements in the treatment of CVD. The availability of
specific HR finally enables to vary e.g. prediction age range and
amount and type of selected CVD risk factors because there is no
dependence on a ‘‘preset’’ model. Therewith, population specific
aging and risk factors burden can be considered. Our linked
MONICA dataset may be regarded as of relatively high quality
with high completeness, participation rate and modest loss to
follow-up. Also, the follow-up time was longer than in most other
studies used for CVD prediction.
Limitations of our Approach
As in most other studies, participants of the Swiss MONICA
had a lower mortality (in particular CVD mortality) than the
general Swiss population. [14] The representativeness of our
sample was also limited because it included only regions from the
French- and Italian-speaking part of Switzerland. In these regions,
CVD mortality is lower than in the German-speaking part of the
country. [23] We also had only one assessment of exposure at
study entry and could not consider change during follow-up.
Moreover, we had no information on whether individuals followed
the advice that has been given upon medical examination after
study inclusion, e.g. cholesterol or blood pressure lowering
treatment. We have, however, no reason to assume that there
were differences between either of these types of medication, e.g.
regarding compliance.
Conclusion
The Brier score based comparison of risk prediction between 1)
the original ESC SCORE model, 2) a recalibrated model and 3) a
new model using coefficients recalculated from the target
population, showed that the new model provided the most valid
CVD risk prediction. CVD risk overestimation from applying the
original SCORE or the recalibrated model to our sample was
mainly due to a smaller contribution of cholesterol to risk
prediction in the new model. Replacing cholesterol with BMI or
blood glucose could make prediction more efficient. Finally, our
approach of using anonymously linked routine and observational
data to predict CVD mortality risk proved to be an efficient way to
obtain country specific CVD risk estimates and to minimize lag
time between data collection and implementation for risk
assessment in clinical practice.
Supporting Information
Figure S1 Chart for absolute 10-year of fatal cardiovas-
cular disease based on the recalibrated ESC SCORE
model* using total cholesterol. MONICA: MONItoring of
trends and determinants in CArdiovscular disease *Low risk
population
(TIF)
Figure S2 Chart for absolute 10-year of fatal cardiovas-
cular disease based on the original ESC SCORE* model
using total cholesterol. *Low risk population
(TIFF)
Figure S3 Bland-Altman plot comparing the original
SCORE model with the new model based on MONICA
with constant limits of agreement (dotted lines). Inter-
pretation of the Bland-Altman plots (S3 and S4) Figure S3 shows a
Bland-Altman plot allowing to compare risk estimates obtained
from the original SCORE model by Conroy et al. [1] with risk
estimates from the new model based on total cholesterol from
MONICA. [14] For each individual, the plot shows the mean of the
two estimated risks to be compared on the x-axis and the difference
between the two individual risk estimates on the y-axis. This allows
the detection of patterns in the differences between the two models
for risk prediction. If most differences lie between the so-called
limits of agreement (dotted lines) and this range of differences has
no clinical relevance, it means that the two methods lead to similar
predictions and are thus exchangeable. This is obviously not the
case in our comparison.
(TIF)
Figure S4 Bland-Altman plot Bland-Altman plot com-
paring the original SCORE model with the new model
based on MONICA with limits of agreement depending
on the mean difference of the risks (dotted lines).
Interpretation of the Bland-Altman plots (S3 and S4). In our
case, the mean difference between both methods (solid line) is close
to zero, but many differences are outside the limits of agreement.
The magnitude of the differences increases with the size of the
individual mean measurement, for which reason the assumption of
constant limits of agreement seems to be inappropriate. Instead,
the limits of agreement have to be dependent of the mean
difference of the risks, which can be seen in Figure S4: Almost all
points lie within the limits of agreement, however, the depicted
differences in predicted risks between the two models are -
especially for higher risks - much too large to be ignored. For this
reason, the two methods don’t seem to be comparable. The Bland-
Altman plots thus underline the results obtained with the Brier
score suggesting that there are substantial differences in predic-
tions from the original and the new model.
(TIF)
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